CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScienceSM, a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp, M.D., Ph.D., chief executive officer of OvaScience, will present at two upcoming investor conferences.
Rodman & Renshaw 14th Annual Healthcare Conference at the Waldorf-Astoria in New York City on Tuesday, September 11, 2012 at 2:25 p.m.
UBS Global Life Sciences Conference at The Grand Hyatt New York on Thursday, September 20, 2012 at 3:30 p.m.
OvaScience is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company’s patented technology is based on the discovery of egg precursor cells (EggPCs), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, OvaScience’s first product candidate, AUGMENTSM, aims to improve egg quality and is designed to increase the success of in vitro fertilization (IVF). OvaScience’s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine.